Boston Scientific Corporation (NYSE: BSX) announces it has entered into a definitive agreement to acquire Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). The purchase price is $27.50 per share, reflecting an enterprise value of approximately $1.16 billion. The TCAR system gained U.S. Food and Drug Administration approval in 2015 and is supported by several clinical studies demonstrating a reduced risk of stroke and other complications associated with traditional open surgery. The products sold by Silk Road Medical are the only devices commercially available for use during the TCAR procedure.
Read the full article: Boston Scientific Announces Agreement to Acquire Silk Road Medical, Inc. //
Source: https://www.prnewswire.com/news-releases/boston-scientific-announces-agreement-to-acquire-silk-road-medical-inc-302175421.html